Editorial Comment
Adverse Hemodynamic Effects of Antiarrhythmic Drugs in Congestive Heart Failure K.E. Hammermeister, MD P atients with congestive heart failure present a variety of unique therapeutic challenges.
One of the more important of these challenges is the treatment of arrhythmias. Patients with congestive heart failure have a high incidence of supraventricular and ventricular arrhythmias, both symptomatic and asymptomatic.1-5 About 40% of deaths in patients with congestive heart failure are sudden and presumed to be the result of an acute arrhythmia. ized trial. The study by Gottlieb and colleagues16 in this issue of Circulation is a direct comparison of immediate hemodynamic changes in a randomized trial of encainide, procainamide, and tocainide in patients with severe congestive heart failure.
Conclusions of the Present Study
Twenty-one patients with refractory congestive heart failure (New York Heart Association functional class III or IV) due to severe left ventricular dysfunction (ejection fraction, less than 0.40; mean, 0.21) were studied after administration of single oral doses of encainide (50 mg), tocainide (600 mg), or procainamide (750 mg). Hemodynamic changes were measured by right heart catheterization 1-2.5 hours after the dose was administered. There were equivalent drops in cardiac index (17-18%) and significant increases in systemic vascular resistance (11-17%) with each of the three drugs. Mean arterial pressure fell with procainamide (6%) but not with encainide or tocainide. Left ventricular filling pressure increased significantly with tocainide and encainide but fell (insignificantly) with procainamide. The investigators concluded that all three drugs may adversely affect left ventricular function in patients with heart failure but that this adverse effect appears to be more severe with encainide or tocainide than with procainamide.
Mechanisms 
